Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuron Limited - American Depositary Shares (NQ: IMRN )

2.150 +0.170 (+8.59%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immuron Limited - American Depositary Shares

< Previous 1 2 3 Next >
Immuron achieves record half yearly Travelan® sales
From Immuron Limited
Via GlobeNewswire
Immuron Clinical Trials Update
From Immuron Limited
Via GlobeNewswire
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
From Immuron Limited
Via GlobeNewswire
Immuron CEO Steven Lydeamore Investor Webinar Presentation
From Immuron Limited
Via GlobeNewswire
Immuron CEO Steven Lydeamore presented at AusBioInvest
From Immuron Limited
Via GlobeNewswire
Immuron Announces Travelan® Clinical Study Cohort 2 commences
From Immuron Limited
Via GlobeNewswire
Immuron achieves record quarterly Travelan® sales
From Immuron Limited
Via GlobeNewswire
Immuron hails record monthly sales of Travelan
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®.... 
Via TheNewswire.com
Immuron achieves record monthly Travelan® sales
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
From Immuron Limited
Via GlobeNewswire
Immuron to present at the Military Health System Research Symposium
From Immuron Limited
Via GlobeNewswire
Immuron welcomes launch of Travelan on Amazon US
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) chief commercial officer Flavio Palumbo speaks with Proactive following the news its Travelan product has launched on Amazon US. 
Via TheNewswire.com
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore to present at Bioshares
From Immuron Limited
Via GlobeNewswire
Immuron Business Update - Ateria Health launches Juvia™ in Australia
From Immuron Limited
Via GlobeNewswire
Immuron FY23 Sales increase 136% on FY22 Sales
From Immuron Limited
Via GlobeNewswire
Immuron Chairman Transition
From Immuron Limited
Via GlobeNewswire
Immuron Business Update: Letter to Shareholders
From Immuron Limited
Via GlobeNewswire
Immuron Initiates Recruitment of Travelan® Clinical Study
From Immuron Limited
Via GlobeNewswire
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
From Immuron Limited
Via GlobeNewswire
Immuron Q3 FY23 Business Update Presentation
From Immuron Limited
Via GlobeNewswire
Q3 FY23 Business Update Webinar Notification
From Immuron Limited
Via GlobeNewswire
Immuron Q3 Sales reach 150% of 1H Sales
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore to host an investor webinar
From Immuron Limited
Via GlobeNewswire
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
From Immuron Limited
Via GlobeNewswire
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
From Immuron Limited
Via GlobeNewswire
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
From Immuron Limited
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.